Memorial Sloan Kettering Cancer Center

https://www.mskcc.org/healthcare-professionals

Refer a Patient to MSKCC: mskcc.org/refer

 

Lymphoma
18:24

Memorial Sloan Kettering Cancer Center

Key Lymphoma Updates From ASH

FEATURING Pallawi Torka
  • 374 views
  • May 2, 2024
16:05

SOHO 2023 Eleventh Annual Meeting

SOHO 2023: What Is High Risk MCL and How Should We Treat It

FEATURING Anita Kumar
  • 194 views
  • October 18, 2023
  • 1
21:58

MedNews Week

The Evolving 1L DLBCL Landscape: POLARIX, Novel Agents and Future Directions

FEATURING Matthew Matasar
  • 290 views
  • August 8, 2023
  • 1
24:57

MedNews Week

Current Management of Newly Diagnosed DLBCL

FEATURING Matthew Matasar
  • 43 views
  • August 8, 2023
18:10

SOHO Brazil 2023

2023 SOHO® Brazil: "Moving Beyond CHOP/CHOEP - How Disease Features Can Guide Treatment in T-Cell Lymphomas"

FEATURING Alison Moskowitz
  • 86 views
  • August 3, 2023
  • 1
38:55

Indy Hematology Review

Managing Indolent and Mantle Cell Lymphomas With Targeted and Cellular Therapies in 2023

FEATURING Gilles Salles
  • 154 views
  • April 18, 2023
  • 1
07:46

ASCO 2022 Conference Coverage

ASCO 2022 on the Initial Safety Run-in Results of the Phase III POLARGO Trial: Polatuzumab Vedotin + Rituximab, Gemcitabine, and Oxaliplatin in R/R DLBCL

FEATURING Matthew Matasar
  • 76 views
  • June 14, 2022
05:16

ASCO 2022 Conference Coverage

ASCO 2022 Updated Interim Analysis of the Randomized Phase 1b/3 Study of Tazemetostat in Combination With Lenalidomide & Rituximab in R/R FL

FEATURING Connie Lee Batlevi
  • 64 views
  • June 8, 2022
34

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 Updated Interim Analysis of the Randomized Phase 1b/3 Study of Tazemetostat in Combination With Lenalidomide & Rituximab in R/R FL

FEATURING Connie Lee Batlevi
  • 19 views
  • June 8, 2022
12:32

Society of Hematologic Oncology Ninth Annual Meeting (SOHO 2021)

SOHO 2021: The Next Wave of Novel Agents in Aggressive B-Cell Lymphoma

FEATURING Gilles Salles
  • 22 views
  • September 30, 2021
10:28

i3 Health

MSKCC 2021 Update on Therapeutic Advances in T-Cell Lymphoma: Subtypes, Novel Therapies, and AEs Management Strategies

FEATURING Steven Horwitz
  • 142 views
  • August 3, 2021
24:05

SOHO Highlights: State of the Art and Next Questions

SOHO Highlights on Non-Bulky cHL: Can We Treat Early Disease With Short-Course ABVD w/o RT Based on Negative Interim PET/CT? Does A+AVD Improve PFS vs. ABVD in Advanced Disease?

FEATURING David Straus
  • 7 views
  • February 3, 2021
11:39

SOHO Highlights: State of the Art and Next Questions

Early Stage cHL Management: Bulky vs. Non-bulky Disease, Better Chemotherapy Options to Improve PFS

FEATURING David Straus
  • 174 views
  • February 3, 2021
15:22

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Update on R/R PTCL: Is There a Single Paradigm Overall? Can Some Standard Treatments Be Curative? What Are the New Agents / Strategies?

FEATURING Steven Horwitz
  • 112 views
  • December 14, 2020
21:36

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Highlights on Newly Diagnosed HL: Is ABVD Chemo Regimen Beneficial for PFS in Early Stage Disease? Can A+AVD Resolve Peripheral Neuropathy in Advanced Stage Disease?

FEATURING David Straus
  • 127 views
  • November 9, 2020
09:59

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Updates on R/R cHL: Can We Improve Chemo With ADCs and CPI? Is Toxicity Excessive Compared to Standard Regimens?

FEATURING David Straus
  • 56 views
  • October 30, 2020
11:13

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Update on DLBCL: CAR-T vs. autoHCT for Early Relapsed Disease and PET+ Sensitive Pts? CAR-T vs alloHCT in Post-Auto Relapse? What Cellular Therapies Will Be Available in the Next 5 yrs?

FEATURING Sergio Giralt
  • 28 views
  • October 27, 2020
07:09

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Next Questions in DLBCL: New Genetic Classification Based Selection of Biomarkers & Therapeutic Strategies to Overcome Immune Tolerance

FEATURING Anas Younes
  • 65 views
  • October 18, 2019
15:47

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Who Is a Candidate for Watch and Wait Therapy in MCL / What Are the Clinical and Biologic Features of Successfully Monitored MCL Patients?

FEATURING Anita Kumar
  • 22 views
  • October 18, 2019
15:41

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

PI3Ki's in Indolent Lymphoma: Overview of Approved Drugs, Trial Based Data on Toxicity and Efficacy of Upcoming PI3Ki's, and the Pre-Clinical Rationale of PI3Ki's+Targeted

FEATURING Andrew Zelenetz
  • 68 views
  • October 18, 2019
15:30

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Marginal Gastric Zone Lymphoma: The Role of Radiation Therapy

FEATURING Joachim Yahalom
  • 22 views
  • October 18, 2019
28:25

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Does RCHOP Stay the Standard of Care After 6 Cycles in Advanced/R DLBCL? + Drug X Strategy

FEATURING Anas Younes
  • 292 views
  • October 18, 2019
13:26

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

The Role of Venetoclax in DLBCL: Efficacy and Safety Results from the CAVALLI Trial, ctDNA Levels as a Promising MRD Detection Method

FEATURING Andrew Zelenetz
  • 90 views
  • October 17, 2019
11:13

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Treating Elderly Patients with Hodgkin Lymphoma - How Much Bleomycin Is Too Much and the Frontline Brentuximab Vedotin Options

FEATURING Alison Moskowitz
  • 184 views
  • October 17, 2019
  • 1
23:38

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Ongoing Efforts to Improve the Safety of CAR T-Cell Therapy: Cytokine Release Syndrome and Neurotoxicity

FEATURING Bianca Santomasso
  • 31 views
  • October 16, 2019